gms | German Medical Science

27. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

Deutsche Liga zur Bekämpfung des hohen Blutdrucks – Deutsche Hypertonie Gesellschaft e. V.

26. bis 29.11.2003, Bonn

In vivo Validation of a new Laser Doppler Scanner device for the assessment of in vivo endothelial function in human microcirculation

Validierung eines neuen Laser Doppler Scanners zur Messung der Endothelfunktion in der menschlichen Mikrozirkulation

Meeting Abstract (Hypertonie 2003)

  • presenting/speaker C. Jürgens - Universitätsklinik Essen, Speedel Developement AG (Essen, D; Basel-Schweiz, CH)
  • J. Mann - Universitätsklinik Essen, Speedel Developement AG (Essen, D; Basel-Schweiz, CH)
  • I. Yildirim - Universitätsklinik Essen, Speedel Developement AG (Essen, D; Basel-Schweiz, CH)
  • H. Bruck - Universitätsklinik Essen, Speedel Developement AG (Essen, D; Basel-Schweiz, CH)
  • R.F. Schäfers - Universitätsklinik Essen, Speedel Developement AG (Essen, D; Basel-Schweiz, CH)
  • T. Philipp - Universitätsklinik Essen, Speedel Developement AG (Essen, D; Basel-Schweiz, CH)
  • R.R. Wenzel - Universitätsklinik Essen, Speedel Developement AG (Essen, D; Basel-Schweiz, CH)

Hypertonie 2003. 27. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Bonn, 26.-29.11.2003. Düsseldorf, Köln: German Medical Science; 2004. Doc03hochV4

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hoch2003/03hoch004.shtml

Veröffentlicht: 11. November 2004

© 2004 Jürgens et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background

Diabetic nephropathy is the leading cause of end-stage renal disease. Blockade of the renin-angiotensin system reduces the progression of renal disease in these patients. Endothelin-A-receptor blockers reduce proteinuria and renal fibrosis in experimental renal disease.

Methods

We investigated the effects of 4 weeks therapy with the ET-A-receptor-antagonist SPP301 in 23 patients with diabetic nephropathy (proteinuria >0.5 g/24 hrs) on top of high-dose angiotensin-1 receptor blockade (ARB) in a double blind, randomised, placebo controlled study. After 4 weeks of stable high-dose ARB-therapy, patients were randomly treated with either 20 mg or 50 mg SPP301 or placebo for 4 weeks in addition to ARB. Primary endpoint was 24-hour proteinuria. Blood pressure and glycaemia were strictly controlled.

Results

Compared to placebo, SPP301 decreased proteinuria dose-dependently (p<0.05). Creatinine clearance was unchanged after 4 weeks. There was no difference in blood pressure among the groups. Total cholesterol and triglycerides tended to decrease under SPP301. The main adverse effects were headache, oedema and a decrease in haemoglobin. No significant increases in liver enzymes were observed.

Conclusion

These promising data indicate that in diabetic nephropathy the endothelin-A-receptor antagonist SPP301 decreases proteinuria on top of high-dose ARBs and thus may have additional benefits to ARBs in the challenging therapy of diabetic nephropathy.

[Fig. 1]